A study to assess the anti-albuminuric effects and variability in response to dapagliflozin in subjects with type 2 diabetes

Trial Profile

A study to assess the anti-albuminuric effects and variability in response to dapagliflozin in subjects with type 2 diabetes

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Jun 2016

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms IMPROVE
  • Most Recent Events

    • 07 Jun 2014 New source identified and integrated (European Clinical Trials Database record: EudraCT2014-000157-37)
    • 07 Jun 2014 According to the European Clinical Trials Database record, status changed from not yet recruiting to recruiting.
    • 02 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top